NCT00463021View on ClinicalTrials.gov

A Phase 4 Study to Determine Dosing of Hectorol® Capsules When Converting From Zemplar® Injection

PHASE4CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

April 30, 2007

Study Completion Date

December 31, 2007

Conditions
Secondary Hyperparathyroidism
Interventions
DRUG

Hectorol (doxercalciferol capsules)

DRUG

Zemplar (paricalcitol injection)

Trial Locations (8)

Unknown

Downey

Paramount

Hudson

Augusta

Decatur

Pittsburgh

Nashville

Norfolk

All Listed Sponsors
lead

Genzyme, a Sanofi Company

INDUSTRY

NCT00463021 - A Phase 4 Study to Determine Dosing of Hectorol® Capsules When Converting From Zemplar® Injection | Biotech Hunter | Biotech Hunter